SYRE Spyre Therapeutics Inc

$SYRE + $VRDN notice the strength here compared to other bios. BO targets imo. Only own a small amount of vrdn

$SYRE strange price action here, everything else is getting sold off yet this seems to be holding up pretty well…

$SYRE reported earnings after the close yesterday. GAAP EPS missed estimates: -$0.94 vs. -$0.79 expected, according to Stock Meadow.

$SYRE 🏥 Spyre Therapeutics, Inc. announced positive topline induction data for SPY003 from Part A of the Phase 2 SKYLINE trial in IBD, completing proof-of-concept for all three monotherapies, while SPY072 showed RA results insufficient to prioritize advancement and missed the primary endpoint in psoriatic arthritis. Actionable market event

Latest company news, October 18, 2026: Spyre announced its UEGW 2026 presentations: an oral talk on October 18 on SPY001, SPY002 and SPY003 in ulcerative colitis, and a preclinical poster on October 19. Spyre Therapeutics ($SYRE): SPY003 And SKYLINE Part A Deeper dive in our hub. Not investment advice.

UBS🏁 $SYRE Buy; $120 PT. $PTGX - JNJ $ABBV LLY PFE BMY MRK ABVX TEVA - SNY TAK SYBX RHHBY UBS said in its initiation report: We view SYRE as the best way to play IBD combination therapies within a market we estimate could reach $40-50B in 2035. Its portfolio of combinations across IL-23, α4B7, and TL1A provides multiple shots on goal and, in our view, favorable odds that at least one regimen succeeds clinically and commercially. Instead of concentrating on a single outcome for the future of IBD, SYRE provides exposure to multiple potential winners. The defining catalyst is the company's broad Phase 2 readout in 2027 in UC (timing TBD; PCD June), which we believe will identify at least one regimen for Phase 3. Near-term volatility is likely as investors react to TL1A class readouts in non-IBD indications, though these indications account for only a small portion of our model. We model $12.5B/$5.5B unadjusted/adjusted 2035 sales for the IBD portfolio, above consensus ~$5B/$3.9B.

Spyre Therapeutics shares rebounded as investors looked past dilution concerns following the company’s recently completed $350 million public offering. The stock is trading below the $85 offering price, attracting buyers who view the discount as an attractive entry point after the recent selling pressure. Separately, Jefferies highlighted Syros Pharmaceuticals as one of its top small- and mid-cap biotech picks for 2027, citing data presented at United European Gastroenterology Week 2026. The firm sees positive implications from real-world findings on combination therapy for Crohn’s disease and ulcerative colitis, although the available disclosure remains limited. Its investment thesis centers on long-acting combination treatments and co-formulations that could deliver differentiated dosing and efficacy in inflammatory bowel disease. A modest recovery in the broader market, supported by lower oil prices and easing geopolitical tensions. $SYRE